← Back to Screener
Nexalin Technology, Inc. Common Stock (NXL)
Price$0.58
Value ScoreF
Growth ScoreC
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)-53.80%
Price vs S&P 500 (4W)55.43%
VGM Score37.22
Market Capitalization$12.55M
All Metrics
Book Value / Share (Quarterly)$0.14
P/TBV (Annual)10.39x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-38.88%
Cash Flow / Share (Quarterly)$-0.26
Price vs S&P 500 (YTD)-1.61%
Gross Margin (TTM)81.99%
Net Profit Margin (TTM)-3022.86%
EPS (TTM)$-0.46
10-Day Avg Trading Volume2.55M
EPS Excl Extra (TTM)$-0.46
Revenue Growth (5Y)4.43%
EPS (Annual)$-0.50
ROI (Annual)-206.94%
Gross Margin (Annual)79.66%
Net Profit Margin (5Y Avg)-3155.40%
Cash / Share (Quarterly)$0.13
Revenue Growth QoQ (YoY)-63.55%
ROA (Last FY)-180.15%
Revenue Growth TTM (YoY)110.34%
EBITD / Share (TTM)$-0.47
Operating Margin (TTM)-3084.13%
Cash Flow / Share (Annual)$-0.30
P/B Ratio4.35x
P/B Ratio (Quarterly)2.48x
Net Income / Employee (Annual)$-1,027,800
EV / Revenue (TTM)41.17x
Net Interest Coverage (TTM)-27.58x
ROA (TTM)-166.45%
EPS Incl Extra (Annual)$-0.50
Current Ratio (Annual)7.25x
Quick Ratio (Quarterly)3.40x
3-Month Avg Trading Volume0.72M
52-Week Price Return-48.74%
Revenue / Employee (TTM)$34,400
Tangible BV / Share (Quarterly)$0.12
P/S Ratio (Annual)41.62x
Asset Turnover (Annual)0.04x
52-Week High$2.00
Operating Margin (5Y Avg)-3252.44%
EPS Excl Extra (Annual)$-0.50
CapEx CAGR (5Y)121.02%
26-Week Price Return-37.87%
Quick Ratio (Annual)6.39x
13-Week Price Return16.86%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)4.07x
Enterprise Value$11.35M
Revenue / Share Growth (5Y)-11.24%
Asset Turnover (TTM)0.06x
Revenue / Employee (Annual)$37,700
Inventory Turnover (Annual)0.22x
Pretax Margin (Annual)-2725.74%
Cash / Share (Annual)$0.26
3-Month Return Std Dev106.59%
Gross Margin (5Y Avg)78.47%
Net Income / Employee (TTM)$-1,041,300
ROE (Last FY)-206.94%
Net Interest Coverage (Annual)-27.97x
EPS Basic Excl Extra (Annual)$-0.50
Receivables Turnover (TTM)9.59x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.46
Receivables Turnover (Annual)15.06x
ROI (TTM)-191.88%
P/S Ratio (TTM)45.56x
Pretax Margin (5Y Avg)-3155.40%
Revenue / Share (Annual)$0.02
Tangible BV / Share (Annual)$0.26
Price vs S&P 500 (52W)-76.95%
Year-to-Date Return9.32%
5-Day Price Return61.50%
EPS Normalized (Annual)$-0.50
ROA (5Y Avg)-801.91%
Net Profit Margin (Annual)-2725.74%
Month-to-Date Return71.69%
Cash Flow / Share (TTM)$-0.63
EBITD / Share (Annual)$-0.51
Operating Margin (Annual)-2781.66%
LT Debt / Equity (Annual)0.00x
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-0.46
P/TBV (Quarterly)2.84x
P/B Ratio (Annual)9.66x
Inventory Turnover (TTM)0.28x
Pretax Margin (TTM)-3022.86%
Book Value / Share (Annual)$0.28
Price vs S&P 500 (13W)7.11%
Beta3.85x
Revenue / Share (TTM)$0.01
ROE (TTM)-191.88%
52-Week Low$0.30
vGradeF
gGradeC
mGradeC
vgmGradeD
Show chart for
Earnings Surprise History
Q1 26-0.11est. -0.10
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.00
4.00
4.00
4.00
Industry Peers — Electromedical Equipment(31)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
NXLNexalin Technology, Inc. Common Stock | F | C | C | $0.58 |
| MDTMedtronic plc | B | D | D | $73.98 |
| MASIMasimo Corporation | D | D | B | $178.59 |
| LIVNLivaNova PLC Ordinary Shares | C | C | B | $73.81 |
| ITGRInteger Holdings Corporation | B | C | C | $90.16 |
| TMDXTransMedics Group, Inc. Common Stock | C | B | F | $67.53 |
| AXGNAxogen, Inc. Common Stock | F | B | B | $38.72 |
| BLFSBioLife Solutions Inc. | F | B | B | $26.63 |
| CNMDCONMED Corporation | A | C | D | $34.65 |
| INMDInMode Ltd. Ordinary Shares | A | D | C | $13.59 |
| CBLLCeriBell, Inc. Common Stock | D | A | C | $17.61 |
About
Nexalin Technology develops bioelectronic neurostimulation devices for treating anxiety and insomnia without medications or psychotherapy. The company's Generation 1 product is a cranial electrotherapy stimulation (CES) device that delivers targeted neural stimulation. As a Class II FDA-cleared device, it represents a non-pharmacological treatment option in the mental health care market.